Chemotherapy's Hidden Cost: Nerve Damage and the Overlooked Solution
Chemotherapy can save lives, but at what cost to the body? A recent study from the University of South Australia reveals a startling gap in post-treatment care. Up to half of chemotherapy patients may be suffering in silence from irreversible nerve damage in their feet, a side effect known as Chemotherapy Induced Peripheral Neuropathy (CIPN).
But here's the shocking part: many patients don't receive the specialized care they desperately need.
Uncovering the Scope of the Problem
In a groundbreaking study, researchers focused on colorectal cancer patients, 82% of whom were treated with Oxaliplatin, a potent neurotoxic chemotherapy drug. The results? A staggering 80% of patients did not seek podiatry services, even though CIPN can lead to severe and permanent foot issues.
The Role of Podiatry in Cancer Care
Podiatrists, experts in lower limb health, can play a crucial role in managing CIPN. They can help reduce pain, prevent falls and ulcers, and improve overall mobility, thereby enhancing patients' quality of life during and after chemotherapy.
And this is where it gets controversial: despite the high prevalence of CIPN, podiatry is often overlooked in routine oncology care. UniSA PhD candidate and podiatrist, Sindhrani Dars, emphasizes the need for change: "Given the debilitating nature of CIPN, podiatry should be an integral part of cancer survivorship care."
Filling the Gap in Care
The study highlights a critical gap in patient awareness and clinical guidelines. Currently, there are no Australian guidelines for CIPN management, and existing clinical pathways exclude podiatry. This oversight leaves patients vulnerable and struggling with a debilitating condition.
"The lack of awareness about podiatry's role in cancer care is concerning," Dars adds. "We need to educate patients and clinicians about the benefits of podiatry and establish better referral systems within oncology."
Taking Action: Clinical Recommendations
To address this issue, the research team, in collaboration with Australian podiatrists, has developed clinical recommendations for managing CIPN. These guidelines are a significant step towards ensuring that patients receive the care they need. Access the recommendations here: https://jfootankleres.biomedcentral.com/articles/10.1186/s13047-023-00632-0
So, what's your take? Are we doing enough to support cancer survivors? Should podiatry be a standard part of oncology care? Share your thoughts and let's spark a conversation about improving the quality of life for those affected by CIPN.
